Allogene Therapeutics

We are looking forward to participating in the upcoming TD Securities Cowen 45th Annual Health Care Conference. Tune in to our fireside chat to hear why we believe in the future of AlloCAR T™ products. Webcasts available in the IR section of our website. #CART Webcasts available on the IR Website: https://lnkd.in/gfptUCzq

We’re excited to announce the expansion of our strategic collaboration with Foresight Diagnostics to enable the development of their investigational minimal residual disease (MRD) assay as a companion diagnostic in the EU, UK, Canada, and Australia in support of the clinical development of our allogeneic CAR T, cema-cel. This expanded partnership brings us closer to unlocking the full potential of CAR T products. Learn more about ALPHA3: https://lnkd.in/gHZW2rkA

Learn how our experience and differentiated science is enabling us to design and develop a CAR T 2.0 product for autoimmune disease that is scalable and could eliminate or reduce lymphodepletion to meet the unique needs of patients. $ALLO #CART #celltherapy #immunotherapy Uncover the Potential of ALLO-329: Allogene.com/Pipeline 

At Allogene, we’ve rewritten the CAR T playbook. Our approach to development and trial design has the potential to deliver ‘off-the-shelf’ CAR T products that dowhat autologous CAR T therapies cannot. $ALLO #CART #celltherapy #immunotherapy Explore Innovation at Allogene: Allogene.com/Science 

Comprehensive Ph1 ALPHA/ALPHA2 data of cema-cel is now published in the American Society of Clinical Oncology (ASCO) Publications Journal of Clinical Oncology. Data demonstrate long-term durability in heavily pre-treated patients with large B-cell lymphoma (LBCL) who received a one-treatment with our investigational allogeneic CAR T product, and 100% complete response in patients with low disease burden – the focus of our innovative ALPHA3 trial in first line LBCL. Learn more about cema-cel: https://lnkd.in/gTYKNGYT

We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. $ALLO #CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design: Allogene.com/Pipeline

OHC hematologist, medical oncologist, and cellular therapy expert James H. Essell, MD was interviewed recently by Liz Bonis of LOCAL 12, WKRC-TV. Our ALPHA3 trial for eligible lymphoma patients tests for residual cancer cells and, if found, patients are eligible for an off-the-shelf CAR-T treatment that may reduce their chance of reoccurrence later in life. Patients testing negative for MRD, like OHC patient Carter Shideler, walk away with the peace of mind that their cancer cells are gone and lower risk of reoccurrence. Read the story here: https://lnkd.in/gqZmtT3w #Hematology #Oncology #CARtherapy #CancerResearch #ClinicalTrials #MRD #CancerAwareness

Investigational AlloCAR T™ products are designed to overcome limitations of today’s autologous therapies and deliver these transformative treatments to more patients where they seek care. $ALLO #CART #celltherapy #immunotherapy Explore the Potential of Expanded CAR T Access: Allogene.com/Pipeline

Allogeneic CAR T has the potential to redefine the future of CAR T. Learn how we are leveraging the unique attributes of investigational AlloCAR T™ products to meet the current and future needs of patients and dramatically expand access to treatment. $ALLO #CART #celltherapy #immunotherapy Discover the Allogeneic Advantage: Allogene.com/Home

We are looking forward to participating in the upcoming Oppenheimer & Co. Inc. investor conference. Tune in to our fireside chats to hear why we believe in the future of AlloCAR T™ products. Webcasts available in the IR section of our website. #CART Upcoming IR Conferences: https://lnkd.in/grbs_jjF